Skip to main content

Outcomes

SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. https://t.co/c3zHT2GfR5
Dr. John Cush @RheumNow( View Tweet )
IL-1 Inhibition in CPPD Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares. https://t.co/7RkE2i6sYY
Dr. John Cush @RheumNow( View Tweet )
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. AS, in particular, poses a diagnostic challenge—its early imaging https://t.co/TH2YIiPPEq
Dr. John Cush @RheumNow( View Tweet )
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
Dr. John Cush @RheumNow( View Tweet )

More on Methotrexate and ILD Risk

To assess the progression of the interstitial lung disease related to Methotrexate (MTX) exposure, and to evaluate the lung involvement in RA non-ILD patients with MTX exposure, a systematic review was performed to assess whether RA patients receiving methotrexate (MTX) are at greater

Read Article

IL-1 Inhibition in CPPD

Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.

The purpose of this analysis is
Read Article
Swedish Birth Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, including preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx

Dr. John Cush @RheumNow( View Tweet )

Why I love the late breaking abstracts https://t.co/jCSfNOoFeT https://t.co/uZWSm9SQAI
Dr. John Cush @RheumNow( View Tweet )
Diagnostic Delays in PsA: A Radiographic Perspective Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25. https://t.co/iLllm7DcCF
Dr. John Cush @RheumNow( View Tweet )
S.Korean study of 481 pts w/ myositis (IIM) - 12.9% (n = 62) had myositis-assoc. cancer. CA risk factos= older age, male, current smoking, dermatomyositis, TIF1γ; but lower risk w/ anti-synthetase synd, overlap myositis, arthritis, & ILD. SCRIM score had AUROC = 0.852 https://t.co/MdU1fRWWgS
Dr. John Cush @RheumNow( View Tweet )

DAHLIAS study - Nipocalimab in Sjögren's Disease

Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.

Read Article
Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. https://t.co/4hoT9dBtPq

Dr. John Cush @RheumNow( View Tweet )

New ACR 2025 Guidelines for Non-Renal Lupus

MedPage Today

Written by Lisa Sammaritano, MD, of the Hospital for Special Surgery in New York City, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should

Read Article
There is a growing burden of #OA among middle-aged adults, rising by 123.7%, from 11.8 million in 1990 to 26.4 million in 2021. 56.5% of incident cases & 38% of prevalent cases occur in middle-aged group (70% higher than the elderly (>60 years) population). Highest in hi-income. https://t.co/JVpZ96qe0E
Dr. John Cush @RheumNow( View Tweet )
Weight Loss as a Therapeutic Goal in PsA PsA is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal https://t.co/Q6IFGn5zCI
Dr. John Cush @RheumNow( View Tweet )
Do Patients with Rheumatic Diseases 'Weather' the Storm? Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25. https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH
Dr. John Cush @RheumNow( View Tweet )
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa
Dr. John Cush @RheumNow( View Tweet )
The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg
Dr. John Cush @RheumNow( View Tweet )
Belimumab Before or After Immunosuppressant Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25 https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn
Dr. John Cush @RheumNow( View Tweet )

Deucravacitinib and Renal Function: Insights from the PAISLEY Trial

In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.

Read Article
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA? Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Dr. John Cush @RheumNow( View Tweet )
The Long View of Diagnostic Delay in Axial Spondyloarthritis At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
Dr. John Cush @RheumNow( View Tweet )
PsA: Impact of Sex Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25. https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Dr. John Cush @RheumNow( View Tweet )
#ACR25 Best Abstracts - Day 2 After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2. https://t.co/gyIWQXVJ50 https://t.co/vjlK41hzFD
Dr. John Cush @RheumNow( View Tweet )
🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology! 🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement! 👉You can read the manuscript in this link: https://t.co/teEscaBVG3 #EMEUNET https://t.co/BKRXTXiQ8U
EMEUNET @EMEUNET( View Tweet )
×